Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIOS: Osimertinib in EGFR+ NSCLC
NCT03239340Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started May 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03239340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239340.